Select a medication above to begin.
EstroGel
estradiol transdermal
Black Box Warnings .
Endometrial Cancer with Unopposed Estrogen in Patients with Intact Uterus
unopposed estrogen use incr. risk of endometrial CA in patients with intact uterus; adding progestogen has been shown to decr. risk of endometrial hyperplasia, a possible precursor to endometrial CA; perform adequate diagnostic measures (including directed or random endometrial sampling) to rule out malignancy in menopausal patient with abnormal genital bleeding of unknown etiology
Adult Dosing .
Dosage forms: GEL (0.06%): 0.75 mg per pump
vasomotor symptoms, moderate-severe menopausal
- [apply 0.75 mg qd]
- Info: consider adding progestogen if intact uterus; consider D/C treatment >4-6wk before surgery if VTE risk
vulvovaginal atrophy, moderate-severe menopausal
- [apply 0.75 mg qd]
- Info: not preferred if local symptoms only; consider adding progestogen if intact uterus; consider D/C treatment >4-6wk before surgery if VTE risk
renal dosing
- [see below]
- renal disease: not defined, caution advised
- HD/PD: not defined, caution advised
hepatic dosing
- [see below]
- hepatic impairment/disease: contraindicated
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.